From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade namesEucrisa, /jˈkrɪsə/ yoo-KRIS
Routes of
Topical (ointment)
ATC code
Legal status
Legal status
CAS Number
PubChem CID
ECHA InfoCard100.225.309 Edit this at Wikidata
Chemical and physical data
Molar mass251.045100 g/mol g·mol−1
3D model (JSmol)

Crisaborole (trade name Eucrisa) is a nonsteroidal topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema) in people two years or older.[1][2] It was approved by U.S. Food and Drug Administration on Dec 14, 2016.[3]

Mechanism of action[edit]

It is a phosphodiesterase-4 inhibitor, mainly acting on phosphodiesterase 4B (PDE4B), which causes inflammation.[4] Chemically, crisaborole is a phenoxybenzoxaborole.[4] Inhibition of PDE4B appears to suppress the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines, proteins believed to be involved in the immune response and inflammation.[4]


The chemical name for crisaborole is 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile.[5]


Crisaborole was developed by Anacor Pharmaceuticals for the topical treatment of psoriasis.[6][4][7] During preclinical and clinical development, crisaborole was called AN2728 and PF-06930164.[8]

See also[edit]


  1. ^ "FDA Approves Eucrisa for Eczema". U.S. Food and Drug Administration. 14 December 2016.
  2. ^ "Eucrisa (crisaborole) Ointment, 2%, for Topical Use. Full Prescribing Information". Anacor Pharmaceuticals, Inc. Palo Alto, CA 94303 USA. Retrieved 17 December 2016.
  3. ^ "FDA approves Eucrisa for eczema" (Press release). U.S. Food and Drug Administration. December 14, 2016.
  4. ^ a b c d Moustafa, F; Feldman, SR (16 May 2014). "A Review of Phosphodiesterase-Inhibition and the Potential Role for Phosphodiesterase 4-Inhibitors in Clinical Dermatology" (PDF). Dermatology Online Journal. 20 (5): 22608. PMID 24852768.
  5. ^ "WHO Drug Information, Vol. 29, No. 3, 2015. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74" (PDF). World Health Information. p. 391. Retrieved 26 April 2016.
  6. ^ Nazarian, R; Weinberg, JM (November 2009). "AN-2728, a PDE4 Inhibitor for the Potential Topical Treatment of Psoriasis and Atopic Dermatitis". Current Opinion in Investigational Drugs. 10 (11): 1236–42. PMID 19876791.
  7. ^ Spreitzer, H (16 August 2016). "Neue Wirkstoffe: Crisaborol". Österreichische Apotheker-Zeitung (in German) (17/2016).
  8. ^ "Crisaborole". AdisInsight. Retrieved 24 July 2017.